Memorial Sloan Kettering Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo
Completed
- Conditions
- MelanomaSquamous Cell CarcinomaBasal Cell CarcinomaNon-Malignant Skin Disorders
- Interventions
- Device: Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00574392
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients
Not Applicable
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Radiation: Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00574353
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Prostate Biomarker Study
Completed
- Conditions
- Prostate Cancer
- Interventions
- Other: Questioners, blood specimens, prostate tissue specimens
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00574899
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸UCLA, Los Angeles, California, United States
Internal Radiation Therapy in Treating Patients With Prostate Cancer
Not Applicable
Completed
- Conditions
- Prostate Cancer
- Interventions
- Other: questionnaire administrationProcedure: quality-of-life assessmentRadiation: brachytherapy
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00573833
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00570401
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Phase 2
Terminated
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Biological: rituximabGenetic: microarray analysisOther: flow cytometryOther: laboratory biomarker analysis
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00567229
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Phase 1
Completed
- Conditions
- Fallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian Cancer
- Interventions
- Biological: filgrastimBiological: therapeutic autologous lymphocytesOther: laboratory biomarker analysis
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT00562640
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma
- Interventions
- Biological: plasmid DNA vaccine therapyOther: flow cytometryOther: immunoenzyme technique
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00561756
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer
Completed
- Conditions
- Colorectal CancerNeoplasm of Uncertain Malignant Potential
- Interventions
- Genetic: DNA methylation analysisGenetic: fluorescence in situ hybridizationGenetic: gene expression analysisGenetic: polymerase chain reactionGenetic: protein expression analysisGenetic: reverse transcriptase-polymerase chain reactionOther: diagnostic laboratory biomarker analysisOther: immunoenzyme techniqueOther: immunohistochemistry staining methodProcedure: biopsyProcedure: therapeutic conventional surgeryRadiation: fludeoxyglucose F 18
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00550628
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cognitive Changes Associated With Breast Cancer Treatment
Completed
- Conditions
- Cognitive Side Effects of Cancer TreatmentsStage I, II and III A Breast CancerBreast Cancer
- Interventions
- Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00550134
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath